Pace Logo

News Category: Life Sciences

Pace® Life Sciences Acquires Biopharma Global, Expanding FDA Regulatory Affairs Strategy and Consulting Capabilities to the Biotechnology and Pharmaceutical Markets

Acquisition allows Pace® to provide full-service regulatory strategy and consulting services to advance FDA submissions across a wide range of therapeutic classes. Minneapolis, MN, September 1, 2022 – Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization (CDMO) and subsidiary of Pace®, ascience and technology company, announced today that it has acquired Biopharma …

Pace® Life Sciences Acquires Biopharma Global, Expanding FDA Regulatory Affairs Strategy and Consulting Capabilities to the Biotechnology and Pharmaceutical Markets Read More »

First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

First Wave BioPharma Chooses Pace® Life Sciences as CDMO Partner. BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the selection of an enhanced enteric microgranule …

First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation Read More »

First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract

Research involves microgranule delivery formulations for adrulipase BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that an abstract titled, “Formulation Development of Enterically Protected Spray Dried …

First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract Read More »

Pace® Life Sciences Acquires Meridian BioGroup, Expanding Regulatory, Compliance, and Validation Capabilities to the Biotechnology and Pharmaceutical Markets

Acquisition allows Pace® to provide regulatory and quality consulting services to support clients throughout the drug development process and improve commercial compliance in FDA-regulated environments. Minneapolis, MN, August 18, 2022 – Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization (CDMO) and subsidiary of Pace® Science and Technology Company, announced today that it …

Pace® Life Sciences Acquires Meridian BioGroup, Expanding Regulatory, Compliance, and Validation Capabilities to the Biotechnology and Pharmaceutical Markets Read More »

Pace® Life Sciences Awarded Bronze Medal from EcoVadis for Sustainability Efforts

Company excels in Labor & Human Rights and Ethics performance for current Corporate Social Responsibility (CSR) Initiatives. Pace® Life Sciences, a division of Pace® Science and Technology Company, is pleased to announce that it has received a Bronze Award for its current state of sustainability. This award signifies that Pace® is in the top 50% …

Pace® Life Sciences Awarded Bronze Medal from EcoVadis for Sustainability Efforts Read More »

Webinar: The Evolution of an NCE’s Suspension Formulation, from pre-GLP Studies to the Pharmacy Shelf

Pharmaceutical Technology hosts “The Evolution of an NCE’s Suspension Formulation, from pre-GLP Studies to the Pharmacy Shelf” – a webinar presented by Dave Barnes, Ph.D., Vice President of Scientific Affairs for Pace® Life Sciences. To watch it live, tune in on Thursday, April 14 at 11 AM EDT. REGISTER HERE REGISTER HERE This presentation focuses …

Webinar: The Evolution of an NCE’s Suspension Formulation, from pre-GLP Studies to the Pharmacy Shelf Read More »

The Changing Landscape of Gene Therapy

Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM Biocompare, The Buyer’s Guide for Life Sciences Published an Article: The Changing Landscape of Gene Therapy, written by Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM at Pace® Life Sciences (PLS). Read the full article

Pace® Life Sciences Acquires Velesco Pharmaceutical Services

Acquisition adds significant experience and expertise in the development of liquid, semi-solid, and oral solid dose products for pre-clinical and clinical use allowing Pace to support a growing number of clients throughout the drug development process. Minneapolis, MN, October 11, 2021 – Pace Analytical Life Sciences®, LLC, a subsidiary of Pace Analytical® Services, LLC, a full-service contract development …

Pace® Life Sciences Acquires Velesco Pharmaceutical Services Read More »

Pace Life Sciences Acquires Drug Delivery Experts, Expanding Capacity and Injectable Drug Product Services

Acquisition allows Pace to support a growing number of clients requiring services throughout the drug development process while adding expertise on drug-device combination products and extended-release injectable technologies. Minneapolis, MN, July 23, 2021 – Pace Analytical Life Sciences®, LLC, a subsidiary of Pace Analytical® Services, LLC, a full-service contract development and manufacturing organization (CDMO), today …

Pace Life Sciences Acquires Drug Delivery Experts, Expanding Capacity and Injectable Drug Product Services Read More »